Filter Results:
(128)
Show Results For
- All HBS Web
(376)
- People (2)
- News (142)
- Research (128)
- Events (2)
- Multimedia (6)
- Faculty Publications (70)
Show Results For
- All HBS Web
(376)
- People (2)
- News (142)
- Research (128)
- Events (2)
- Multimedia (6)
- Faculty Publications (70)
Sort by
- 10 May 2017
- Research & Ideas
Amazon Web Services Changed the Way VCs Fund Startups
cloud-based software and service companies, which could take advantage of AWS to decrease costs, versus others like biotechs that were less impacted by the new technologies. “The goal was to try and understand whether VCs were allocating... View Details
- 16 Feb 2004
- Research & Ideas
HBS Center Focuses on Europe
growth decisions facing Direvo, a young German biotech firm, when one of their partners suddenly wants to become an investor and the company expands both its customer and investor base in Europe and not just in Germany. Still a relatively... View Details
Keywords: by Cynthia Churchwell
- 23 Oct 2018
- First Look
New Research and Ideas, October 23, 2018
case:https://hbsp.harvard.edu/product/318082-PDF-ENG Harvard Business School Case 318-083 Sandra Brown Goes Digital (B): The Commitment Decision Sandra Brown, a middle manager at a biotech company who has led internal and external... View Details
Keywords: Dina Gerdeman
- 12 Sep 2006
- First Look
First Look: September 12, 2006
organization's relational capacity. The benefits will reverberate throughout every dimension of the company's work. Financial Contracting in Biotech Strategic Alliances Authors:David T. Robinson and Toby E. Stuart Periodical:Journal of... View Details
Keywords: Sean Silverthorne
- 07 Oct 2014
- First Look
First Look: October 7
(MMRC), and brought together a diverse body of academics, researchers, pharmaceutical and biotech companies, physicians, and patients to combine their efforts around the disease. The MMRF had helped facilitate clinical trials for... View Details
Keywords: Sean Silverthorne
- 25 Feb 2014
- First Look
First Look: February 25
recent firm performance? Purchase this case: http://hbr.org/product/say-on-pay-qualcomm-inc-shareholders-vote-maybe-in-2012/an/114005-PDF-ENG Harvard Business School Case 213-047 Aqua Bounty Valuation of a pre-revenue biotech company at... View Details
Keywords: Sean Silverthorne
- 20 Nov 2006
- Research & Ideas
Open Source Science: A New Model for Innovation
four-and-a-half year period. Problems involved everything from biotech to consumer products and agrochemicals. Thanks to broadcasting, nearly one-third of the previously unsolved problems found successful solutions. "Innovations... View Details
Keywords: by Martha Lagace
- 07 Feb 2017
- First Look
First Look at New Research: February 7
case:https://cb.hbsp.harvard.edu/cbmp/product/517027-PDF-ENG Harvard Business School Case 617-022 Alnylam Pharmaceuticals: Building Value from the IP Estate (B) The leader of a pioneering biotech company in the siRNA space weighs his... View Details
Keywords: Sean Silverthorne
- 03 May 2011
- First Look
First Look: May 3
Business Model Gary P. Pisano, Ryan Johnson, and Carin-Isabel KnoopHarvard Business School Case 611-046 In the biotech world, the 18-year-old Munich-based company MorphoSys was a rarity: it was profitable. The company achieved this... View Details
Keywords: Sean Silverthorne
- 18 Aug 2011
- Lessons from the Classroom
Business Plan Contest: 15 Years of Building Better Entrepreneurs
asking, is this the right business model? But there are no answers. The market and technology are constantly changing," Riesenfeld remarks. Important Sounding Board The biotech industry presents similar challenges in a space littered with... View Details
- 17 Mar 2009
- First Look
First Look: March 17, 2009
Download the paper: http://www.hbs.edu/research/pdf/09-099.pdf Cases & Course MaterialsAvid Radiopharmaceuticals: The Venture Debt Question Harvard Business School Case 809-086 The CEO of a promising biotech company must decide how... View Details
Keywords: Martha Lagace
- 12 May 2009
- First Look
First Look: May 12, 2009
this situation, donations are likely to decline, investment surplus has declined and biotech partners are challenged to finance joint projects as well as their own operations. Beall is striving to find a cure for cystic fibrosis while... View Details
Keywords: Martha Lagace
- 04 Jun 2007
- Research & Ideas
Is Health Care Making You Better—or Dead?
technological innovation, which is how the biotechs and some of the medical devices can get through these hurdles. But for a health service innovation, the payment hurdles are so massive it's masochistic. Then if you go into competition... View Details
- 28 Apr 2009
- First Look
First Look: April 28, 2009
testing, and business strategy at Targanta Therapeutics, a biotech company preparing its first new drug application to the FDA. In October 2007, Mark Leuchtenberger, president and CEO of Targanta—which has just held a successful... View Details
Keywords: Martha Lagace
- 21 Apr 2009
- First Look
First Look: April 21, 2009
this case: http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=807106 Note on Biotech Business Development Harvard Business School Note 807-032 Describes the business development process in biotechnology... View Details
Keywords: Martha Lagace
- 19 Sep 2012
- Research & Ideas
Book Excerpt: “The Architecture of Innovation”
but the fund achieved impressive successes. For instance, it invested in biotech firms like Amgen, Cephalon, and Sepracor, and coinvested with major venture firms such as Kleiner Perkins and New Enterprise Associates. Its compensation... View Details
- 04 Apr 2022
- Research & Ideas
Tech Hubs: How Software Brought Talent and Prosperity to New Cities
move to one of the big tech clusters like San Francisco,” Kerr says. “Likewise, if you are a biotech entrepreneur, there are enormous advantages to being in the Boston area. But there are also a lot of inventors who work in spaces that... View Details
Keywords: by Rachel Layne
- 24 May 2011
- First Look
First Look: May 24
case:http://cb.hbsp.harvard.edu/cb/product/211086-PDF-ENG Innovation and Growth at Actelion Ltd Gary P. Pisano, Daniela Beyersdorfer, and Ruth DittrichHarvard Business School Case 611-065 : In late 2010, Jean-Paul Clozel, CEO of the Swiss View Details
Keywords: Sean Silverthorne
- 19 Mar 2006
- Research & Ideas
Unlocking Your Investment Capital
Neither an asset's cost nor its size specifies its riskiness. For example, consider two assets, $1 billion of a single-drug biotech stock and $1 billion of U.S. Treasury bonds: Each has the same cost and size but they have radically... View Details
- 08 Sep 2010
- First Look
First Look: September 8, 2010
for a cure; the doubts and obstacles he experiences along the way; and the current options Kremer faces, from returning home to spend time with family to founding a new biotech venture. Through this stark, realistic, and inspiring... View Details
Keywords: Sean Silverthorne